Intensity Therapeutics, Inc. (INTS): Total Liabilities
$2.23M
As of 2025-12-31
$2.31M
As of 2026-06-30
-31.3%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.23M | +19.3% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $1.86M | -54.9% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $4.13M | -39.7% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $6.86M | n/a | 2024-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $2.23M | +19.3% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $50.02M | +31.1% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $129.8K | -89.8% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $5.10M | -58.3% |
Compare INTS, BCAB, ENTX, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗